Introduction: Folate receptor− α (FR− α) has been established as a membrane marker for
ovarian cancer. In addition, it is frequently overexpressed in other major types of epithelial …

The folate receptor (FR) is a confirmed tumor-associated antigen that binds folate and folate–
drug conjugates with very high affinity and shuttles these bound molecules inside cells via …

Targeted delivery via selective cellular markers can potentially increase the efficacy and
reduce the toxicity of therapeutic agents. The folate receptor (FR) has two glycosyl …

While conventional therapies have improved the outcome for patients with ovarian cancer,
the disease still accounts for the most gynecological cancer-related deaths. The …

Conventional cancer treatment modalities have several limitations including lack of sufficient
efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In …

Introduction: The prognosis of patients affected by ovarian cancer has not substantially
changed in the last decades and improving survival still remains a challenge. In the …

Folate targeted drug delivery has emerged as an alternative therapy for the treatment and
imaging of many cancers and inflammatory diseases. Due to its small molecular size and …

Increasing evidence suggests that the folate receptor (FR) can be exploited for therapeutic
applications. This endocytosing protein is well known to functionally mediate the cellular …

Ovarian cancer is the most common cause of gynecological cancer-related mortality, with
the majority of women presenting with advanced disease; although chemotherapeutic …

Background In cancer therapy, molecularly targeted agents have the potential to maximize
antitumor efficacy while minimizing treatment-related toxicity. However, these agents may …